Chromosomal Abnormality Genetic Testing: Methods, Samples, and Applications

Chromosomal abnormality genetic testing is a specialized laboratory discipline that identifies numerical and structural chromosome aberrations linked to birth defects, developmental disorders, infertility, and pregnancy loss. This article provides a technical overview of sample types, testing items, analytical methods, and clinical applications of modern cytogenetic and cytogenomic testing performed by accredited third-party laboratories.

Technical Overview

Chromosomal abnormality genetic testing refers to the laboratory detection of deviations in chromosome number or structure within human cells. Numerical abnormalities (aneuploidy, polyploidy, and mosaicism) involve the gain or loss of entire chromosomes, while structural abnormalities include deletions, duplications, inversions, translocations, ring chromosomes, and marker chromosomes. Chromosome abnormalities occur in approximately one in 150 to 200 live births and are the leading identified cause of congenital malformations, intellectual disability, and developmental delay. They are also responsible for roughly half of first-trimester spontaneous miscarriages and contribute significantly to infertility and recurrent implantation failure.

Modern testing integrates classical cytogenetics, such as G-banded karyotyping and fluorescence in situ hybridization (FISH), with molecular cytogenomic technologies, including chromosomal microarray analysis (CMA), multiplex ligation-dependent probe amplification (MLPA), and low-pass whole-genome sequencing (CNV-seq). Together, these methods provide analytical resolution ranging from whole-chromosome level down to submicroscopic copy number variants (CNVs) of approximately 50 to 100 kilobases. Testing is performed in accredited third-party laboratories operating under quality management frameworks such as ISO 15189 for medical laboratories and ISO/IEC 17025 for testing laboratories, with karyotypes and genomic coordinates reported according to the International System for Human Cytogenomic Nomenclature (ISCN) and results interpreted in accordance with professional technical standards from bodies such as the American College of Medical Genetics and Genomics (ACMG).

Testing Samples

Peripheral Blood

Peripheral blood is the most common sample type for postnatal constitutional testing. A volume of 2 to 5 mL collected in sodium heparin tubes is cultured for 68 to 72 hours, arrested in metaphase, and processed for G-banded karyotyping. Peripheral blood is suitable for evaluating patients with suspected chromosomal syndromes, couples with infertility or recurrent pregnancy loss, and family members requiring carrier confirmation of a known rearrangement.

Amniotic Fluid

Amniotic fluid obtained by amniocentesis, typically performed at 16 to 22 weeks of gestation, is the primary sample for mid-trimester prenatal diagnosis. A volume of approximately 20 mL supports both rapid molecular assays, such as QF-PCR, and cultured-cell karyotyping. CMA or CNV-seq can be applied directly to uncultured amniocytes to reduce the risk of culture failure and culture artifacts.

Chorionic Villi

Chorionic villus sampling (CVS), performed between 11 and 14 weeks of gestation, provides the earliest invasive diagnostic sample, usually 10 to 20 mg of villous tissue. Because CVS samples placental tissue, confined placental mosaicism must be considered during interpretation, and confirmatory amniocentesis is sometimes recommended when mosaic results are detected.

Umbilical Cord Blood

Cord blood obtained by cordocentesis (percutaneous umbilical blood sampling), typically after 18 weeks of gestation, is used for rapid karyotyping when fetal anomalies are identified later in pregnancy, or when confirmatory testing is required following abnormal screening or mosaic results from other sources.

Products of Conception

Fetal or placental tissue collected from miscarriage or termination procedures is tested to determine whether the pregnancy loss was caused by aneuploidy, polyploidy, or structural abnormality. SNP-array-based methods are particularly valuable for this sample type because they can simultaneously detect triploidy and maternal cell contamination, both of which are common technical challenges in products-of-conception testing.

Maternal Plasma (Cell-Free Fetal DNA)

A maternal blood draw of approximately 10 mL from 10 weeks of gestation onward provides circulating cell-free DNA for non-invasive prenatal testing (NIPT). This screening approach evaluates placental DNA fragments and requires no invasive procedure, making it suitable for screening common fetal trisomies and sex chromosome aneuploidies in both high-risk and average-risk pregnancies.

Buccal Swabs and Saliva

Non-invasive buccal swabs or saliva samples are used for follow-up family studies, confirmation of postnatal findings, and testing of individuals who cannot provide blood. DNA extracted from these samples is suitable for molecular methods such as CMA, MLPA, and sequencing-based assays, but not for standard karyotyping.

Embryo Biopsy Samples

Trophectoderm biopsies from blastocyst-stage embryos generated during in vitro fertilization are analyzed using preimplantation genetic testing for aneuploidy (PGT-A). Whole-genome amplification is performed on a few biopsied cells, followed by array or low-pass sequencing methods to assess embryo ploidy prior to transfer.

Testing Items

Typical testing panels for chromosomal abnormality detection include the following categories:

• Whole-chromosome aneuploidy detection, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome)
• Sex chromosome abnormalities, including 47,XXY (Klinefelter syndrome), 47,XXX, 47,XYY, and mosaic sex chromosome complements
• Polyploidy detection, including triploidy and tetraploidy, primarily in prenatal and products-of-conception samples
• Microdeletion and microduplication syndromes, such as 22q11.2 deletion syndrome, 5p- (cri-du-chat syndrome), 4p- (Wolf-Hirschhorn syndrome), Prader-Willi and Angelman syndrome regions at 15q11-q13, Williams syndrome at 7q11.23, and 1p36 deletion syndrome
• Structural rearrangements, including balanced and unbalanced reciprocal translocations, Robertsonian translocations, inversions, ring chromosomes, and marker chromosomes
• Genome-wide submicroscopic copy number variants (CNVs) at resolutions of approximately 50 kb to 1 Mb, depending on the platform used
• Mosaicism assessment, with routine reporting thresholds commonly set at 20% for karyotyping and lower thresholds for array and sequencing platforms
• Rapid prenatal aneuploidy testing for chromosomes 13, 18, 21, X, and Y by QF-PCR or FISH, including maternal cell contamination assessment
• Non-invasive prenatal screening for common trisomies, sex chromosome aneuploidies, and selected microdeletion syndromes using maternal plasma cell-free DNA

Testing Methods

G-Banded Karyotyping

Karyotyping remains the reference method for detecting both numerical abnormalities and balanced structural rearrangements. Cells are cultured, arrested in metaphase, G-banded, and analyzed under light microscopy at a resolution of approximately 320 to 550 bands, corresponding to a structural detection limit of roughly 5 to 10 Mb. Karyotyping is the only routine technique that visualizes balanced translocations and inversions genome-wide, which is essential for evaluating couples with recurrent miscarriage and for distinguishing true mosaicism across multiple cell lines.

Fluorescence In Situ Hybridization (FISH)

FISH uses labeled DNA probes targeted to centromeres, locus-specific regions, or subtelomeric sequences, hybridized to interphase nuclei or metaphase chromosomes. It delivers rapid results within 24 to 48 hours and is applied for rapid prenatal aneuploidy detection, confirmation of microdeletion syndromes, characterization of marker chromosomes, and follow-up of previously identified rearrangements in family members.

Chromosomal Microarray Analysis (CMA)

CMA encompasses array comparative genomic hybridization (aCGH) and SNP-array platforms. It detects genome-wide CNVs at a resolution of approximately 50 to 100 kb without requiring dividing cells. SNP arrays additionally identify long contiguous stretches of homozygosity, triploidy, and maternal cell contamination. Professional guidelines, including ACMG standards, recommend CMA as a first-tier diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorder, or multiple congenital anomalies.

QF-PCR and MLPA

Quantitative fluorescent PCR (QF-PCR) amplifies chromosome-specific short tandem repeat markers to rapidly exclude common trisomies and confirm sample origin, making it a standard adjunct to invasive prenatal diagnosis. Multiplex ligation-dependent probe amplification (MLPA) uses probe ligation and amplification to assess targeted submicroscopic regions and known microdeletion syndromes with minimal DNA input, providing an efficient confirmation and carrier-testing tool.

Low-Pass Whole Genome Sequencing (CNV-seq)

CNV-seq performs massively parallel sequencing at low depth of coverage, typically 0.05x to 0.1x, followed by bioinformatic read-depth analysis across the genome. It detects aneuploidies, polyploidies (with SNP-informed workflows), and CNVs down to approximately 100 kb to 1 Mb, depending on sequencing depth and sample quality. Its high throughput, objective analysis pipeline, and low DNA input requirement make it widely used for products-of-conception testing, prenatal diagnosis, and preimplantation genetic testing.

Non-Invasive Prenatal Testing (NIPT)

NIPT analyzes cell-free DNA in maternal plasma using whole-genome or targeted sequencing. Clinical validation studies demonstrate detection sensitivity above 99% for trisomy 21 with specificity above 99%, alongside strong performance for trisomies 18 and 13 and sex chromosome aneuploidies. NIPT is a screening test, and all positive results must be confirmed by invasive diagnostic testing such as amniocentesis with karyotyping and CMA.

Quality Assurance and Reporting

Testing workflows are governed by documented quality systems aligned with ISO 15189, ISO/IEC 17025, and corresponding national laboratory standards such as GB/T 22576. Each analysis includes validated sample identity tracking, maternal cell contamination testing where applicable, analytical validation of resolution and detection thresholds, and standardized reporting using ISCN nomenclature. Clinically significant CNVs are classified as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign in accordance with ACMG interpretation frameworks, and reports include recommendations for parental testing and genetic counseling where appropriate.

Applications

Chromosomal abnormality genetic testing supports clinical decision-making across the full reproductive and postnatal continuum:

• Prenatal diagnosis following abnormal NIPT results, advanced maternal age, abnormal ultrasound findings, or positive serum screening
• Population-scale prenatal screening for common trisomies through cell-free DNA analysis
• Preimplantation genetic testing for aneuploidy (PGT-A) to prioritize euploid embryos during in vitro fertilization and improve transfer outcomes
• Recurrent pregnancy loss evaluation through products-of-conception testing and parental karyotyping
• Infertility workups, including detection of sex chromosome aneuploidies and Y chromosome structural abnormalities in males with azoospermia or severe oligospermia
• Postnatal diagnostic evaluation of children with developmental delay, intellectual disability, autism spectrum disorder, dysmorphic features, or multiple congenital anomalies
• Pre-conception carrier assessment for individuals with balanced translocations identified in prior family testing, enabling risk counseling and reproductive planning
• Differential evaluation of disorders of sex development and ambiguous genitalia through combined karyotyping and molecular testing

FAQ

What is the difference between karyotyping and chromosomal microarray?

Karyotyping examines cultured metaphase chromosomes under microscopy and reliably detects aneuploidy, mosaicism, and balanced structural rearrangements at a resolution of roughly 5 to 10 Mb. Chromosomal microarray analyzes DNA directly at 50 to 100 kb resolution and detects many submicroscopic CNVs invisible to karyotyping, but it cannot detect truly balanced rearrangements or low-level mosaicism below its validated thresholds. The two methods are complementary, and the appropriate choice depends on the clinical indication.

Is NIPT a diagnostic test?

No. NIPT is a highly sensitive screening test based on placental cell-free DNA. Although detection rates for trisomy 21 exceed 99%, false-positive and false-negative results can occur due to placental mosaicism, vanishing twins, maternal chromosomal factors, or malignancy. All positive NIPT results should be confirmed through invasive diagnostic procedures such as amniocentesis with karyotyping or CMA before clinical decisions are made.

How long does testing take?

Typical turnaround times are 24 to 48 hours for rapid FISH or QF-PCR, 7 to 14 calendar days for CMA, MLPA, or CNV-seq, and 10 to 21 working days for cultured karyotyping, depending on cell culture success and reporting requirements. Urgent prenatal cases are often expedited by combining a rapid molecular assay with a confirmatory method.

What is the smallest abnormality that can be detected?

Detection limits depend on the platform: karyotyping typically resolves changes of 5 to 10 Mb, CNV-seq resolves approximately 100 kb to 1 Mb depending on sequencing depth, and SNP arrays or high-density aCGH platforms routinely resolve CNVs of 50 to 100 kb. Very small variants below platform resolution, as well as single-gene and sequence-level variants, require targeted molecular or whole-exome and whole-genome sequencing approaches.

Why do both members of a couple with recurrent miscarriage need karyotyping?

Approximately 3 to 5% of couples with recurrent pregnancy loss carry a balanced translocation or inversion. While carriers are usually phenotypically normal, their gametes can receive unbalanced chromosome complements, resulting in recurrent miscarriage or offspring with congenital anomalies. Identifying a carrier allows accurate recurrence-risk counseling and guides options such as prenatal diagnosis or preimplantation genetic testing for structural rearrangements (PGT-SR).

Can these tests detect all genetic diseases?

No. Chromosomal abnormality testing focuses on large-scale copy number and structural changes. It does not reliably detect single-nucleotide variants, small insertions and deletions, triplet repeat expansions, methylation defects outside targeted assays, or variants in regions not covered by a given platform. Suspicion of a monogenic disorder requires sequence-based testing, often guided by clinical genetics consultation.

How is a variant of uncertain significance handled?

CNVs that cannot be definitively classified as pathogenic or benign are reported as variants of uncertain significance (VOUS). Laboratories recommend parental sampling to determine whether the variant is inherited or de novo, and periodic re-evaluation is advised because classification may change as public databases and published evidence evolve. Genetic counseling is recommended for all VOUS results.